Gilead loses again in PrEP patent fight with HHS, sending dispute to federal court

In its high-profile patent feud with the U.S. government over HIV prevention medicines, Gilead Sciences has suffered its second consecutive loss.

Following a similar decision earlier this month, the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board decided not to strike up inter partes reviews (IPR) of patents held by the U.S. government. Gilead had challenged the patents in August, but for the second time this month, the board decided Gilead wouldn’t be likely to succeed.